Tirzepatide's dual receptor mechanism How tirzepatide works: Dual GIP/GLP-1 receptor agonist Single molecule, two pathways GIP (glucose-dependent insulinotropic polypeptide) + GLP-1 Weekly subcutaneous injection FDA approved for diabetes and obesity GIP pathway effects: Enhances insulin secretion Improves insulin sensitivity Promotes fat metabolism Reduces inflammation Works synergistically with GLP-1 GLP-1 pathway effects: Suppresses appetite (central brain effects) Slows gastric emptying (moderate) Increases satiety Reduces glucagon Improves glucose control Combined tirzepatide results: 15-22% average body weight loss (monotherapy) Superior to semaglutide (GLP-1 alone) Well-tolerated in trials Approved and available See our tirzepatide dosing guide , semaglutide vs tirzepatide , and peptides for weight loss at SeekPeptides
Response to electroconvulsive therapy in bipolar depression The effect of electroconvulsive therapy (ECT) on bipolar depression has not been investigated in RCTs, and the maintenance effect is controversial, with potential side effects including cognitive effects
Laser treatments sometimes cause a snapping sensation on the skin
Storage: Store at room temperature, out of the reach of small children
This work is supported by the Natural Products & Nanobiotechnology Research Lab, Saveetha Institute of Basic Medical Sciences (SIBMS), Saveetha Institute of Medical and Technical Sciences (SIMATS), (Saveetha University), Thandalam, Chennai, Tamil Nadu 602105, India Conflict of interest The author declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest
L-ornithine HCL, L-arginine, anti-caking agents: magnesium salts of fatty acids, silicon dioxide
